UroGen Pharma Ltd (NASDAQ: URGN) on Friday, plunged -5.88% from the previous trading day, before settling in for the closing price of $10.71. Within the past 52 weeks, URGN’s price has moved between $9.78 and $20.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 16454.91% over the last five years. The company achieved an average annual earnings per share of 11.91%. With a float of $34.99 million, this company’s outstanding shares have now reached $42.19 million.
The firm has a total of 201 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.27%, operating margin of -93.7%, and the pretax margin is -124.59%.
UroGen Pharma Ltd (URGN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of UroGen Pharma Ltd is 17.09%, while institutional ownership is 87.89%. The most recent insider transaction that took place on Jan 31 ’25, was worth 50,698. In this transaction Chief Medical Officer of this company sold 4,551 shares at a rate of $11.14, taking the stock ownership to the 145,666 shares. Before that another transaction happened on Jan 31 ’25, when Company’s General Counsel sold 7,379 for $11.14, making the entire transaction worth $82,202. This insider now owns 26,468 shares in total.
UroGen Pharma Ltd (URGN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 11.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 50.33% during the next five years compared to 5.89% growth over the previous five years of trading.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
UroGen Pharma Ltd (URGN) is currently performing well based on its current performance indicators. A quick ratio of 8.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -2.71 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Analysing the last 5-days average volume posted by the [UroGen Pharma Ltd, URGN], we can find that recorded value of 0.34 million was lower than the volume posted last year of 0.36 million. As of the previous 9 days, the stock’s Stochastic %D was 46.97%. Additionally, its Average True Range was 0.53.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 7.77%, which indicates a significant decrease from 10.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.70% in the past 14 days, which was higher than the 45.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.80, while its 200-day Moving Average is $13.12. Now, the first resistance to watch is $10.60. This is followed by the second major resistance level at $11.12. The third major resistance level sits at $11.38. If the price goes on to break the first support level at $9.82, it is likely to go to the next support level at $9.56. Now, if the price goes above the second support level, the third support stands at $9.04.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
Market capitalization of the company is 425.37 million based on 23,454K outstanding shares. Right now, sales total 82,710 K and income totals -102,240 K. The company made 25,200 K in profit during its latest quarter, and -23,670 K in sales during its previous quarter.
